Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
311 stopped studies mapped to Glioblastoma and descendants · 89% state a reason
Over the 311 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02283944 | TMS Electrochemotherapy for Glioblastoma Multiforme | Phase 2 | withdrawn | Nov 5, 2014 | University of Aarhus | Device for multi coil TMS no longer supported | Other (stated, no rule matched) |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme… | Phase 1 / Phase 2 | terminated | Apr 27, 2010 | M.D. Anderson Cancer Center | Unanticipated Toxicities | Safety / toxicity |
| NCT03393000 | Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed…(INTACT) | Phase 3 | terminated | Jan 8, 2018 | Diffusion Pharmaceuticals Inc | Business decision on behalf of the Sponsor. | Sponsor / business decision |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | terminated | Jan 27, 2014 | St. Joseph's Hospital and Medical Center, Phoenix | excessive protocol deviations due to strict nature of diet requirements | Other (stated, no rule matched) |
| NCT02743078 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Phase 2 | terminated | Apr 19, 2016 | RTOG Foundation, Inc. | Treatment now available commercially | Other (stated, no rule matched) |
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | Phase 1 | withdrawn | Apr 22, 2021 | Jonsson Comprehensive Cancer Center | The P.I. is not prepared to move forward at this thime | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | Phase 3 | terminated | Feb 5, 2018 | AbbVie | The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma… | Other (stated, no rule matched) |
| NCT03980249 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of… | Early Phase 1 | withdrawn | Jun 10, 2019 | West Virginia University | No funding | Funding |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | Phase 1 | terminated | Sep 14, 2017 | Gary Archer Ph.D. | We are halting enrollment of this study. | Enrollment / accrual |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | Phase 2 | terminated | Jan 16, 2015 | SynerGene Therapeutics, Inc. | not stated | Not stated |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or… | Phase 1 | terminated | Oct 2, 2014 | Pediatric Brain Tumor Consortium | Data for the primary objectives is complete and the MTD identified in Stratum II. | Other (stated, no rule matched) |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse… | Phase 2 | terminated | May 2, 2016 | Meyer Children's Hospital IRCCS | Study was terminated due to high heterogeneity of enrolled patients | Enrollment / accrual |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma… | Phase 2 | terminated | Nov 20, 2014 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study was terminated due to lack of clinical activity and not due to safety reasons. | Safety / toxicity |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03151772 | Bioavailability of Disulfiram and Metformin in Glioblastomas(INSIDE) | Early Phase 1 | terminated | May 12, 2017 | Sahlgrenska University Hospital | Problems with including patients | Other (stated, no rule matched) |
| NCT03506139 | Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma | Phase 2 | withdrawn | Apr 23, 2018 | John M. Buatti | Not funded | Funding |
| NCT02919332 | Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With… | — | withdrawn | Sep 29, 2016 | Jonsson Comprehensive Cancer Center | No participants were enrolled | Enrollment / accrual |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in… | Phase 2 | withdrawn | Jan 9, 2017 | Jonsson Comprehensive Cancer Center | Final contract negotiations | Other (stated, no rule matched) |
| NCT00943462 | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of… | — | withdrawn | Jul 22, 2009 | Centre hospitalier de l'Université de Montréal (CHUM) | No eligible patients could be recruited. | Enrollment / accrual |
| NCT03115138 | Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of…(Bi-GLAM) | N/A | terminated | Apr 14, 2017 | Centre Hospitalier Universitaire, Amiens | investigator choice | Investigator |
| NCT03707457 | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First… | Phase 1 | terminated | Oct 16, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding/material support withdrawn | Funding |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | Phase 1 | terminated | Mar 30, 2020 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | Phase 2 | terminated | Nov 23, 2011 | Northwestern University | Slow accrual to some cohorts | Enrollment / accrual |
| NCT01349036 | A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | Phase 2 | terminated | May 6, 2011 | Daiichi Sankyo | Business Decision | Sponsor / business decision |
| NCT03573986 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and… | Phase 1 | terminated | Jun 29, 2018 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent…(Toca5) | Phase 2 / Phase 3 | terminated | Apr 10, 2015 | Tocagen Inc. | Sponsor Decision | Sponsor / business decision |
| NCT02754362 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With… | Phase 2 | withdrawn | Apr 28, 2016 | NYU Langone Health | Due to personnel changes / departure of Dr. Chi. | Other (stated, no rule matched) |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | Phase 2 | terminated | Jun 8, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01117155 | A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas | — | withdrawn | May 5, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00031538 | Genetic Analysis of Brain Tumors | — | terminated | Mar 7, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03843814 | Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma | N/A | terminated | Feb 18, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Imaging results were not sufficient or of good quality; therefore, we will not move further with… | Other (stated, no rule matched) |
| NCT00984438 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for… | Phase 1 / Phase 2 | withdrawn | Sep 25, 2009 | University of Cincinnati | No accrual | Enrollment / accrual |
| NCT00035373 | Eligibility Screening of Patients With Central Nervous System Tumors for the National… | — | terminated | May 3, 2002 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03480867 | Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A…(PARADIGMA) | Phase 1 | withdrawn | Mar 29, 2018 | McGill University Health Centre/Research Institute of the McGill University Health Centre | competing study was opened by the surgeon after this trial was opened | Other (stated, no rule matched) |
| NCT03246113 | Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma | Phase 1 | terminated | Aug 11, 2017 | New York State Psychiatric Institute | Lack of subject interest due to study design | Other (stated, no rule matched) |
| NCT04002804 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With…(Dendr2) | Phase 1 | terminated | Jul 1, 2019 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Temozolomide does not favour immune response; secondary GBM to be excluded | Other (stated, no rule matched) |
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance…(Gliadel-MRS) | — | withdrawn | Mar 27, 2008 | Weill Medical College of Cornell University | not stated | Not stated |
| NCT02395692 | Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma | Phase 2 | terminated | Mar 24, 2015 | National Cancer Institute (NCI) | Pre-specified response criteria not met to proceed to next stage of study. | Other (stated, no rule matched) |
| NCT03403803 | Prognosis and Therapeutic Biomarkers for Glioblastoma Patients | — | terminated | Jan 19, 2018 | Baylor Research Institute | Were not able to meet enrollment goal due to inclusion/exclusion criteria | Enrollment / accrual |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | — | withdrawn | Jun 5, 2017 | Duke University | Failure to enroll | Enrollment / accrual |
| NCT01186406 | Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed… | Phase 2 | terminated | Aug 23, 2010 | Duke University | Study ended early due to toxicity | Safety / toxicity |
| NCT01044966 | A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With… | Phase 1 / Phase 2 | terminated | Jan 8, 2010 | Medical University of South Carolina | The study was terminated due to lack of adequate patient enrollment into trial. | Enrollment / accrual |
| NCT03293888 | Spectral Analysis Probe to Identify Glioblastoma Cells | — | terminated | Sep 26, 2017 | University of Oklahoma | PI Relocation | Other (stated, no rule matched) |
| NCT00734526 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly… | Phase 1 | terminated | Aug 14, 2008 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00895960 | Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma | Phase 1 | terminated | May 11, 2009 | M.D. Anderson Cancer Center | Sponsor withdrew support; Study did not progress to Phase II. | Other (stated, no rule matched) |
| NCT02850744 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of… | Phase 2 | terminated | Aug 1, 2016 | PIQUR Therapeutics AG | not stated | Not stated |
| NCT02062372 | Spatial Analysis and Validation of Glioblastoma on 7 T MRI | N/A | terminated | Feb 13, 2014 | Maastricht Radiation Oncology | Expectation that within the set time period insufficient patients will be included, so endpoints… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 20, 2021source: clinicaltrials